Intrust Bank NA Has $412,000 Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Intrust Bank NA cut its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 10.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,385 shares of the medical equipment provider’s stock after selling 403 shares during the period. Intrust Bank NA’s holdings in Zimmer Biomet were worth $412,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. PFG Advisors grew its stake in Zimmer Biomet by 4.6% in the fourth quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock valued at $231,000 after acquiring an additional 84 shares during the period. Quent Capital LLC grew its stake in Zimmer Biomet by 21.6% in the fourth quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock valued at $63,000 after acquiring an additional 92 shares during the period. Pinnacle Associates Ltd. grew its stake in Zimmer Biomet by 5.0% in the third quarter. Pinnacle Associates Ltd. now owns 2,020 shares of the medical equipment provider’s stock valued at $227,000 after acquiring an additional 97 shares during the period. Financial Advocates Investment Management grew its stake in Zimmer Biomet by 3.8% in the third quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider’s stock valued at $295,000 after acquiring an additional 97 shares during the period. Finally, Stokes Family Office LLC grew its stake in Zimmer Biomet by 4.1% in the third quarter. Stokes Family Office LLC now owns 2,498 shares of the medical equipment provider’s stock valued at $280,000 after acquiring an additional 99 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. JPMorgan Chase & Co. upped their price objective on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. Evercore ISI upped their price objective on Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 9th. Barclays upped their price objective on Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research report on Monday, February 12th. Finally, Canaccord Genuity Group reaffirmed a “hold” rating and set a $130.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $139.39.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $119.56 on Thursday. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. The stock’s 50 day moving average price is $125.65 and its two-hundred day moving average price is $119.91. The firm has a market capitalization of $24.56 billion, a price-to-earnings ratio of 24.45, a P/E/G ratio of 2.21 and a beta of 1.03. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.00 and a 12-month high of $149.25.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.15 by $0.05. The firm had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.88 earnings per share. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.08 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were paid a $0.24 dividend. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.80%. Zimmer Biomet’s dividend payout ratio is 19.63%.

Insider Transactions at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares in the company, valued at $5,677,929.90. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.95% of the stock is owned by corporate insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.